Literature DB >> 18813036

Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention.

Gregory A Nuttall1, Michael J Brown, John W Stombaugh, Peter B Michon, Matthew F Hathaway, Kevin C Lindeen, Andrew C Hanson, Darrell R Schroeder, William C Oliver, David R Holmes, Charanjit S Rihal.   

Abstract

BACKGROUND: The duration of time that elective noncardiac surgery (NCS) should be delayed after percutaneous coronary intervention (PCI) with bare metal stents (BMSs) is unknown.
METHODS: This large, single-center, retrospective study examined the relation between complication rate in patients with BMSs undergoing NCS and the duration of time between PCI and NCS. Primary endpoints included in-hospital major adverse cardiac events (death, myocardial infarction, stent thrombosis, or repeat revascularization with either coronary artery bypass grafting or PCI of the target vessel) and bleeding events. The relation between the events and the timing of noncardiac surgery after PCI with BMS was assessed using univariate analysis and multiple logistic regression.
RESULTS: From January 1, 1990, to January 1, 2005, a total of 899 patients were identified. The frequency of major adverse cardiac events was 10.5% when NCS was performed less than 30 days after PCI with BMS, 3.8% when NCS was performed between 31 and 90 days after PCI with BMS, and 2.8% when NCS was performed more than 90 days after PCI with BMS. In univariate and multivariate analyses, a shorter time interval between PCI with BMS and noncardiac surgery was significantly associated with increased incidence of major adverse cardiac events (univariate: P < 0.001; odds ratio = 4.0; 95% confidence interval, 2.0-8.3; multivariate: P = 0.006; odds ratio = 3.2; 95% confidence interval, 1.5-6.9). Bleeding events were not associated with time between PCI with BMS and NCS or with the use of antiplatelet therapy in the week before NCS.
CONCLUSIONS: The incidence of major adverse cardiac events is lowest when NCS is performed at least 90 days after PCI with BMS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813036     DOI: 10.1097/ALN.0b013e318186ddf8

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  25 in total

1.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  [The risk of stent thrombosis in the perioperative setting].

Authors:  Martin Norbert Vicenzi
Journal:  Wien Med Wochenschr       Date:  2009-10

3.  Case scenario: a patient on dual antiplatelet therapy with an intracranial hemorrhage after percutaneous coronary intervention.

Authors:  Bhiken I Naik; Ellen C Keeley; Daryl R Gress; Zhiyi Zuo
Journal:  Anesthesiology       Date:  2014-09       Impact factor: 7.892

4.  The management of patients on dual antiplatelet therapy undergoing orthopedic surgery.

Authors:  Han Jo Kim; Lawrence F Levin
Journal:  HSS J       Date:  2010-07-27

5.  2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Developed in collaboration with the American College of Surgeons, American Society of Anesthesiologists, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Vascular Medicine Endorsed by the Society of Hospital Medicine.

Authors:  Lee A Fleisher; Kirsten E Fleischmann; Andrew D Auerbach; Susan A Barnason; Joshua A Beckman; Biykem Bozkurt; Victor G Davila-Roman; Marie D Gerhard-Herman; Thomas A Holly; Garvan C Kane; Joseph E Marine; M Timothy Nelson; Crystal C Spencer; Annemarie Thompson; Henry H Ting; Barry F Uretsky; Duminda N Wijeysundera
Journal:  J Nucl Cardiol       Date:  2015-02       Impact factor: 5.952

Review 6.  Management of antiplatelet therapy inpatients at risk for coronary StentThrombosis undergoing non-cardiac surgery.

Authors:  Zuzana Motovska
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

Review 7.  Bridge with intravenous antiplatelet therapy during temporary withdrawal of oral agents for surgical procedures: a systematic review.

Authors:  Nuccia Morici; Lorenzo Moja; Valentina Rosato; Alice Sacco; Antonio Mafrici; Silvio Klugmann; Maurizio D'Urbano; Carlo La Vecchia; Stefano De Servi; Stefano Savonitto
Journal:  Intern Emerg Med       Date:  2014-01-14       Impact factor: 3.397

8.  Noncardiac surgery for patients with coronary artery stents: timing is everything.

Authors:  Jeffrey J Rade; Charles W Hogue
Journal:  Anesthesiology       Date:  2008-10       Impact factor: 7.892

9.  Coronary artery disease: to cath or not to cath? When and how best to cath: those are the remaining questions.

Authors:  Roberta Rossini; Giuseppe Musumeci; Eliano Pio Navarese; Giuseppe Tarantini
Journal:  Am J Cardiovasc Dis       Date:  2013-02-17

10.  Preoperative Evaluation of the Surgical Patient.

Authors:  Frederick T O'Donnell
Journal:  Mo Med       Date:  2016 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.